Here, we report that induction of lymphopenia followed by PBMC reinfusion, combined with an autologous whole tumor cell vaccine and the continuous infusion of GM-CSF at the vaccine site, is a safe and feasible approach in resectable lung cancer patients. This evidence concerns the gene CSF2 and neoplasm.